{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:26:40Z","timestamp":1779229600459,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00228-023-03464-w","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T08:06:16Z","timestamp":1675757176000},"page":"485-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7964","authenticated-orcid":false,"given":"Mehmet Zahid","family":"Kocak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhiddin","family":"Er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffer","family":"Ugrakli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engin","family":"Hendem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melek Karakurt","family":"Eryilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"3464_CR1","unstructured":"Cancer IAfRo (2020) Cancer IAfRo: GLOBOCAN 2020: estimated cancer incidence, mortality, and prevalence worldwide in 2020. In Website"},{"key":"3464_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1586\/17474124.2015.1001743","volume":"9","author":"PM Kasi","year":"2015","unstructured":"Kasi PM, Hubbard JM, Grothey A (2015) Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. Expert Rev Gastroenterol Hepatol 9:273\u2013276","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3464_CR3","unstructured":"Roche Registration Limited (2009)\u00a0Avastin (bevacizumab) summary of product characteristics \u00a0(last update 10\/19\/2016). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avastin-epar-product-information_en.pdf\u00a0Accessed 12 Dec 2022."},{"key":"3464_CR4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"3464_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O\u2019Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB III (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539\u20131544","journal-title":"J Clin Oncol"},{"key":"3464_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1634\/theoncologist.2012-0003","volume":"17","author":"JH Strickler","year":"2012","unstructured":"Strickler JH, Hurwitz HI (2012) Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17:513\u2013524","journal-title":"Oncologist"},{"key":"3464_CR7","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo A-M (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645","journal-title":"J Clin Oncol"},{"key":"3464_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0959-8049(12)72403-6","volume":"48","author":"F Heitz","year":"2012","unstructured":"Heitz F, du Bois A, Harter P, Kurzeder C, Lubbe D, Vergote I, Plante M, Pfisterer J (2012) Impact of beta-blocker medication in patients with platinum sensitive recurrent ovarian cancer\u2013a combined analysis of 2 prospective multicenter trials by the AGO study group, NCIC-CTG and EORTC-CTG. Eur J Cancer 48:186\u2013187","journal-title":"Eur J Cancer"},{"key":"3464_CR9","first-page":"1","volume":"4","author":"GN Armaiz-Pena","year":"2013","unstructured":"Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P (2013) Src activation by \u03b2-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 4:1\u201312","journal-title":"Nat Commun"},{"key":"3464_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm1447","volume":"12","author":"PH Thaker","year":"2006","unstructured":"Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939\u2013944","journal-title":"Nat Med"},{"key":"3464_CR11","doi-asserted-by":"crossref","unstructured":"Stewart CL, Warner S, Ito K, Raoof M, Wu GX, Lu W-P, Kessler J, Kim JY, Fong Y (2018) Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg 55:330","DOI":"10.1067\/j.cpsurg.2018.08.004"},{"key":"3464_CR12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.21873\/invivo.11708","volume":"33","author":"R Hashizume","year":"2019","unstructured":"Hashizume R, Kawahara H, Ogawa M, Suwa K, Eto K, Yanaga K (2019) CA19-9 concentration after first-line chemotherapy is prognostic predictor of metastatic colon cancer. In Vivo 33:2087\u20132093","journal-title":"In Vivo"},{"key":"3464_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clcc.2019.01.005","volume":"18","author":"AI Neugut","year":"2019","unstructured":"Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O\u2019Neil DS, Accordino MK, Kiran RP, Wright J, Hershman DL (2019) FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-medicare data. Clin Colorectal Cancer 18:133\u2013140","journal-title":"Clin Colorectal Cancer"},{"key":"3464_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.18632\/oncotarget.182","volume":"1","author":"HM Schuller","year":"2010","unstructured":"Schuller HM (2010) Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1:466\u2013469","journal-title":"Oncotarget"},{"key":"3464_CR15","doi-asserted-by":"publisher","first-page":"10357","DOI":"10.1158\/0008-5472.CAN-06-2496","volume":"66","author":"EV Yang","year":"2006","unstructured":"Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh P-E (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357\u201310364","journal-title":"Cancer Res"},{"key":"3464_CR16","doi-asserted-by":"publisher","first-page":"35462","DOI":"10.1074\/jbc.M110.109579","volume":"285","author":"MM Shahzad","year":"2010","unstructured":"Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee J-W, Jennings NB, Bottsford-Miller J (2010) Stress effects on FosB-and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 285:35462\u201335470","journal-title":"J Biol Chem"},{"key":"3464_CR17","doi-asserted-by":"publisher","first-page":"29919","DOI":"10.1074\/jbc.M611539200","volume":"282","author":"MB Nilsson","year":"2007","unstructured":"Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE (2007) Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282:29919\u201329926","journal-title":"J Biol Chem"},{"key":"3464_CR18","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1172\/JCI40802","volume":"120","author":"AK Sood","year":"2010","unstructured":"Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK (2010) Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120:1515\u20131523","journal-title":"J Clin Invest"},{"key":"3464_CR19","first-page":"2866","volume":"61","author":"K Masur","year":"2001","unstructured":"Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by \u03b2-blockers. Cancer Res 61:2866\u20132869","journal-title":"Cancer Res"},{"key":"3464_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060021","volume":"8","author":"JM Stiles","year":"2013","unstructured":"Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, Modiano JF, Kokta V, Boucheron LE, Mitchell DC (2013) Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One 8:e60021","journal-title":"PLoS ONE"},{"key":"3464_CR21","doi-asserted-by":"publisher","first-page":"6174664","DOI":"10.1155\/2022\/6174664","volume":"2022","author":"Y Olgun","year":"2022","unstructured":"Olgun Y, Aktas S, Sutay S, Ecevit MC (2022) The effect of bevacizumab and propranolol on nasal polyposis. Int J Clin Prac 2022:6174664","journal-title":"Int J Clin Prac"},{"key":"3464_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","volume":"25","author":"S Zhong","year":"2016","unstructured":"Zhong S, Yu D, Zhang X, Chen X, Yang S, Tang J, Zhao J, Wang S (2016) \u03b2-blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prev 25:440\u2013448","journal-title":"Eur J Cancer Prev"},{"key":"3464_CR23","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.2147\/OTT.S167422","volume":"11","author":"Z Na","year":"2018","unstructured":"Na Z, Qiao X, Hao X, Fan L, Xiao Y, Shao Y, Sun M, Feng Z, Guo W, Li J (2018) The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients. Onco Targets Ther 11:4913","journal-title":"Onco Targets Ther"},{"key":"3464_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jss.2013.11.661","volume":"186","author":"R Musselman","year":"2014","unstructured":"Musselman R, Li W, Gomes T, Mamdani M, Haggar F, Moloo H, Boushey R, Al-Omran M, Al-Obeed O, VanWalraven C (2014) Association between beta blocker usage and cancer survival in a large, matched population study among hypertensive patients. J Surg Res 186:639\u2013640","journal-title":"J Surg Res"},{"key":"3464_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","volume":"65","author":"HH Grytli","year":"2014","unstructured":"Grytli HH, Fagerland MW, Foss\u00e5 SD, Task\u00e9n KA (2014) Association between use of \u03b2-blockers and prostate cancer\u2013specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 65:635\u2013641","journal-title":"Eur Urol"},{"key":"3464_CR26","doi-asserted-by":"crossref","unstructured":"Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Ridolfi F, Cascinu S (2015) Prognostic value for incidental antihypertensive therapy with \u03b2-blockers in metastatic colorectal cancer. Medicine 94(24)","DOI":"10.1097\/MD.0000000000000719"},{"key":"3464_CR27","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers11121856","volume":"11","author":"O Fiala","year":"2019","unstructured":"Fiala O, Ostasov P, Sorejs O, Liska V, Buchler T, Poprach A, Finek J (2019) Incidental use of beta-blockers is associated with outcome of metastatic colorectal cancer patients treated with bevacizumab-based therapy: a single-institution retrospective analysis of 514 patients. Cancers 11:1856","journal-title":"Cancers"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03464-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03464-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03464-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T09:04:00Z","timestamp":1679648640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03464-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3464"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03464-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Ethics Committee of Necmettin Erbakan University (approval no: 2022\/3779).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was not obtained as the study was a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}